SAF312

DRUG3 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Chronic Ocular PainNeurogenic Bladder DisorderNeurogenic Bladder, SpasticNeurogenic Bladder, UninhibitedNeurogenic Dysfunction of the Urinary BladderNeurogenic Urinary BladderPostoperative Ocular Pain After PRK Surgery

Phase 2

Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions

TerminatedNCT01598103

Novartis PharmaceuticalsNeurogenic Bladder Disorder, Neurogenic Bladder, Spastic, Neurogenic Bladder, Uninhibited +2

Start: 2012-01-31End: 2012-09-30Updated: 2020-12-19

Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery

CompletedNCT02961062

Novartis PharmaceuticalsPostoperative Ocular Pain After PRK Surgery

Start: 2016-12-01End: 2018-02-21Updated: 2021-10-06

Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)

CompletedNCT04630158

Novartis PharmaceuticalsChronic Ocular Pain

Start: 2021-04-21End: 2023-06-08Updated: 2024-10-09